Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

Bibliography

• KANNEL WB: Framingham study insights into hypertensive risk of cardiovascular disease. Hypertens. Res. (1995) 18:181–196.
   PubMedGoogle Scholar
• HADAR I, KOTCHEN TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA (2003) 290:199–206.
   PubMedGoogle Scholar
• BURT VL, WELTON P, ROCELLA EJ et al.: Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension (1995) 25:305–313.
   Google Scholar
• WOLF-MATER K, COOPER RS, BANE GAS JR et al.: Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA (2003) 289:2363–2369.
   Google Scholar
• DEVEREUX RB, ALDERMAN MH: The role of preclinical cardiovascular disease in the evolution from risk factor exposure to the development of clinical morbid events. Circulation (1993) 88:1444–1455.
   PubMed Web of Science ®Google Scholar
• KOREN MJ, DEVEREUX RB, CASALE PN et al.: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann. Intern. Med. (1991) 114:345–352.
   PubMed Web of Science ®Google Scholar
• MENSAH GA, PAPPAS TW, KOREN MJ et al.: Comparison of classification of hypertension severity by blood pressure level and World Health Organization criteria for prediction of concurrent cardiac abnormalities and subsequent complications in essential hypertension. Hypertension (1993) 11:1429–1440.
   Google Scholar
• LEVY D, GARRISON RJ, SAVAGE DD et al.: Prognostic implications of echocardiographically-determined left ventricular mass in the Framingham Heart Study. N Engl. I Med. (1990) 322:1561–1566.
   PubMed Web of Science ®Google Scholar
• BIKKINA M, LEVY D, EVANS JC et al.: Left ventricular mass and the risk of stroke in an elderly cohort: The Framingham Study. JAMA (1994) 272:33–36.
   PubMed Web of Science ®Google Scholar
• GHALI JK, LIAO Y, SIMMONS B et al: The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann. Intern. Med. (1992) 117:831–836.
   PubMed Web of Science ®Google Scholar
• BOLOGNESE L, DELLAVESA P, ROSSI L et al.: Prognostic value of left ventricular mass in uncomplicated acute myocardial infarction and one-vessel coronary artery disease. Am. Cardiol (1994) 73:1–5.
   PubMed Web of Science ®Google Scholar
• LEVY D, SALOMON M, AGOSTINO RB et al: Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation (1994) 90:1786–1793.
   PubMed Web of Science ®Google Scholar
• MUIESAN ML, SALVETTI M, RIZZONI D et al.: Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. Hypertens. (1995) 13:1091–1105.
   Google Scholar
• VERDECCHIA P, SCHILLACI G, BORGIONI C et al.: Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation (1998) 97:48–54.
   PubMed Web of Science ®Google Scholar
• MATHEW J, SLEIGHT P, LONN E et al:Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation (2001) 104:1615–1621.
   PubMed Web of Science ®Google Scholar
• BLOOD PRESSURE LOWERING TREATMENT TRIALISTS' COLLABORATION: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs.Lancet (2000) 356:1955–1964.
   Google Scholar
• KJELDSEN SE, JULIUS S, HEDNER T,HANSSON L: Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. Blood Press. (2001) 10:190–192.
   PubMed Web of Science ®Google Scholar
• WILLIAMS GR, JIANG JG, MATCHAR DB, SAMSA GP: Incidence and occurrence of total (first-ever and recurrent) stroke. Stroke (1999) 30:2523–2528.
   PubMed Web of Science ®Google Scholar
• AMERICAN HEART ASSOCIATION: Heart Disease and Stroke Statistics - 2003 Update. American Heart Association. Dallas, Texas, USA (2002).
   Google Scholar
• MURRAY CJL, LOPEZ AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet (1997) 349:1498–1504.
   PubMed Web of Science ®Google Scholar
• GOA KL, WAGSTAFF AJ: Losartan potassium. A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs (1996) 15:820–845.
   Google Scholar
• SCHIFFRIN EL, PARK JB, INTENGAN HD, TOUYZ RM: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation (2000) 101:1653–1659.
   PubMed Web of Science ®Google Scholar
• STRAWN WB, CHAPPELL MC, DEAN RH et al.: Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation (2000) 101:1586–1593.
   PubMed Web of Science ®Google Scholar
• GOLIGORSKY MS, CHEN J, BRODSKY S: Endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide. Hypertension (2001) 37:744–748.
   PubMed Web of Science ®Google Scholar
• GUTTERMAN DD: Vascular dysfunction in hyperglycemia. Is protein kinase C the culprit? Circ. Res. (2002) 90:5–7.
   Google Scholar
• ANDERSEN S, BLOUCH K, BIALEK J et al.: Glomerular permselectivity in early stages of overt diabetic nephropathy. Kidney Int. (2000) 58:2129–2137.
   PubMed Web of Science ®Google Scholar
• BENIGNI A, REMUZZI G: How renal cytokines and growth factors contribute to renal disease progression. Am. J. Kidney Dis. (2001) 37:S21–S24.
   Google Scholar
• TAAL MW, BRENNER BM: Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int. (2000) 57:1803–1817.
   PubMed Web of Science ®Google Scholar
• HOLLENBERG NK: ACE inhibition, angiotensin II receptor blockade and diabetic nephropathy. In: The Kidney and Hypertension M Diabetes Mellitus. Mogensen CE (Ed.), Kluwer Academic Publishers, Boston, USA (2000):417–422.
   Google Scholar
• SINGH R, ALAVI N, SINGH AK, LEEHEY DJ: Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes (1999) 48:2066–2073.
   PubMed Web of Science ®Google Scholar
• HOIEGGEN A, ALDERMAN MH, KJELDSEN SE et al.: The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. (2004) 65:1041–1049.
   PubMed Web of Science ®Google Scholar
• BURNIER M, RUTS CHMANN B, NUSSBERGER J et al.: Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension (1993) 22:339–347.
   PubMed Web of Science ®Google Scholar
• SOFFER BA, WRIGHT JT, PRATT JHet al.: Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension (1995) 26:112–117.
   Google Scholar
• BURNIER M, ROCH-RAMEL F, BRUNNER HR: Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int. (1996) 49:1787–1790.
   PubMed Web of Science ®Google Scholar
• KLEIN R, KLEIN BE, CORNONI JC et al.: Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch. Intern. Med. (1973) 132:401–410.
   Google Scholar
• BENGTSSON C, LAPIDUS L, STENDAHL C, WALDENSTROM J: Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med. Scand. (1988) 224:549–555.
   Google Scholar
• LEHTO S, RONNEMAA T, PYORALA K,LAAKSO M: Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke (1996) 27:63–68.
   PubMed Web of Science ®Google Scholar
• ALDERMAN MH, COHEN H, MADHAVAN S, KIVLIGHN S: Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension (1999) 34:144–150.
   PubMed Web of Science ®Google Scholar
• FREEDMAN DS, WILLIAMSON DF, GUNTER EW, BYERS T: Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am. I Epidemiol (1995) 141:637–644.
   PubMed Web of Science ®Google Scholar
• PERSKY VW, DYER AR, IDRIS-SOVEN E et al.: Uric acid: a risk factor for coronary heart disease? Circulation (1979) 59:969–977.
   Google Scholar
• CULLETON BE LARSON MG, KANNEL WB, LEVY D: Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann. Intern. Med. (1999) 131:7–13.
   PubMedGoogle Scholar
• BUTLER R, MORRIS AD, BELCH JJ et al.: Allopurinol normalizes endothelial dysfunction in Type 2 diabetics with mild hypertension. Hypertension (2000) 35:746–751.
   PubMed Web of Science ®Google Scholar
• DOEHNER W, SCHOENE N, RAUCHHAUS Met al.: Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation (2002) 105:2619–2624.
   Google Scholar
• LEYVA F, ANKER S, SWAN JVV et al.: Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Ear: Heart J. (1997) 18:858–865.
   PubMed Web of Science ®Google Scholar
• MUSTARD JF, MURPHY EA, OGRZYLO MA et al.: Blood coagulation and platelet economy in subjects with primary gout. Can. Med. Assoc. 1 (1963) 89:1207-1211.
   Google Scholar
• HOIEGGEN A, FOSSUM E, REIMS H, KJELDSEN SE: Serum uric acid and hemorheology in borderline hypertensives and in subjects with established hypertension and left ventricular hypertrophy. Blood Press. (2003) 12:1–7.
   Google Scholar
• NEWLAND H: Hyperuricemia in coronary, cerebral and peripheral arterial disease: an explanation. Med. Hypotheses (1975) 1:152–155.
   PubMedGoogle Scholar
• MESSERLI FH, FROHLICH ED, DRESLINSKI GR et al.: Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Arch. Intern. Med. (1980) 93:817–821.
   Google Scholar
• MATTEI P, ARZILLI F, GIOVANNETTI R et al.: Microalbuminuria and renal haemodynamics in essential hypertension. Eur. Clin. Invest. (1997) 27:755–760.
   PubMed Web of Science ®Google Scholar
• JOHNSON RJ, KANG D-H, FEIG D et al.: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension (2003) 41:1183–1190.
   Google Scholar
• CONLIN PR, SPENCE JD, WILLIAMS B et al.: Angiotensin II antagonists for hypertension: are there differences in efficacy? Am. J. Hypertens. (2000) 13:418–426.
   Web of Science ®Google Scholar
• DAHLOF B, DEVEREUX RB, KJELDSEN SE et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359:995–1003.
   PubMed Web of Science ®Google Scholar
• LINDHOLM LH, IBSEN H, DAHLOF B et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359:1004–1010.
   PubMed Web of Science ®Google Scholar
• DAHLOF B, DEVEREUX RB, DE FAIRE U et al.: The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study. Rationale, design and methods. Am. I Hypertens. (1997) 10:705–713.
   Google Scholar
• LINDHOLM LH, IBSEN H, BORCH-JOHNSEN K et al.: Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. Hypertens. (2002) 20:1879–1886.
   Google Scholar
• WHO STUDY GROUP: Diabetes mellitus (technical report series 727). World Health Organization, Geneva, Switzerland (1985).
   Google Scholar
• WORLD HEALTH ORGANIZATION (WHO): Department of Noncommunicable Disease Surveillance. WHO, Geneva, Switzerland (1999):1–59.
   Google Scholar
• IBSEN H, WACHTELL K, OLSEN MH et al.: Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension and left ventricular hypertrophy? A LIFE substudy. Hypertens. (2004) 22:1805–1811.
   Google Scholar
• KJELDSEN SE, DAHLOF B, DEVEREUX RB et al.: Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. JAMA (2002) 288:1491–1498.
   PubMed Web of Science ®Google Scholar
• JULIUS S, ALDERMAN MH, BEEVERS G et at Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: The LIFE study. J. Ain. Coll. Cardiol (2004) 43:1047–1055.
   PubMed Web of Science ®Google Scholar
• DEVEREUX RB, DAHLOF B, GERDTS E et at Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol. The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial. Circulation (2004) 110:1456–1462.
   PubMed Web of Science ®Google Scholar
• OKIN PM, DEVEREUX RB, JERN S et al.: Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol. Circulation (2003) 108:684–690.
   PubMed Web of Science ®Google Scholar
• FORHEAD AJ, PIPKIN FB, SUTHERLAND MF et al.: Changes in the maternal and fetal renin-angiotensin systems in response to angiotensin II Type I receptor blockade and angiotensin-converting enzyme inhibition in pregnant sheep during late gestation. Exp. Physic] (1997) 82:761–776.
   PubMedGoogle Scholar
• KROBOT K, GERTH W, DIENER HC: Estimates of losartan-induced versus atenolol-induced reduction of strokes in patients with arterial hypertension and electrocardiographic left ventricular hypertrophy in Germany. .1. Hypertens. (2003) 21 (Suppl. 4):5174.
   Google Scholar
• DAHLOF B, BURKE TA, KROBOT K et al.: Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J. Human Hypertens. (2004) 18:367–373.
   PubMed Web of Science ®Google Scholar
• BRENNER BM, COOPER ME, DE ZEEUW D et al.: Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl. .1. Med. (2001) 345:861–869.
   Google Scholar